Ligand Pharmaceuticals (LGND) Assets Average (2011 - 2026)

Ligand Pharmaceuticals' Assets Average history runs 16 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• In Q1 2026, Assets Average rose 67.43% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 67.43% YoY), while the FY2025 annual figure was $1.3 billion, up 44.73% from the prior year.
• Assets Average came in at $1.5 billion for Q1 2026 at Ligand Pharmaceuticals, up from $1.5 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.5 billion in Q1 2026 to a low of $763.7 million in Q3 2023.
• A 5-year average of $1.0 billion and a median of $923.6 million in 2025 frame the typical range for Assets Average.
• Across the five-year window, Assets Average sank 34.5% in 2023 and jumped 67.43% in 2026, its largest moves.
• Ligand Pharmaceuticals' Assets Average stood at $906.6 million in 2022, then declined by 14.16% to $778.2 million in 2023, then grew by 21.86% to $948.3 million in 2024, then soared by 60.15% to $1.5 billion in 2025, then increased by 1.82% to $1.5 billion in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $1.5 billion, $1.5 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison